These data and others from the Venclexta/Venclyxto clinical development programme will be featured in more than 50 abstracts at the 61st
'Venclexta/Venclyxto plus anti-CD20 monoclonal antibody-based regimens continue to demonstrate improved long-term outcomes for people with chronic lymphocytic leukaemia,' said
The pivotal phase III CLL14 study evaluated the combination of Venclexta/Venclyxto plus Gazyva/Gazyvaro (obinutuzumab) in people with previously untreated CLL, who had co-existing medical conditions. At a median follow-up of more than three years (39.57 months), when all patients had been off therapy for a minimum of two years, Venclexta/Venclyxto plus Gazyva/Gazyvaro showed high response rates, including MRD-negativity.
Specifically: Higher rates of MRD-negativity in peripheral blood (76% vs. 35%; p
(C) 2019 Electronic News Publishing, source